This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

RTI Biologics Announces Positive Clinical Results For BioCleanse®-Processed BTB Allografts Used In ACL Reconstruction

RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading provider of orthopedic and other biologic implants, is pleased to announce the results of a recent randomized prospective clinical study of BioCleanse ®-processed bone-patellar tendon-bone (BTB) allografts used in anterior cruciate ligament (ACL) reconstruction surgery. The study was published in the peer reviewed journal, Knee Surgery, Sports Traumatology, Arthroscopy, in December 2012.

The article compares the clinical outcomes of BTB allografts processed using RTI’s patented BioCleanse Tissue Sterilization Process with a control group consisting of aseptically-processed allografts from the three U.S. tissue banks that provide this type of allograft. According to the American Association of Tissue Banks’ 13 th edition of Standards for Tissue Banking, aseptic processing refers to the processing of tissue using methods to prevent, restrict or minimize contamination with microorganisms from the environment, processing personnel, and/or equipment. A total of 67 patients undergoing ACL reconstruction at six independent investigation sites were evaluated at six, 12 and 24 months. After randomization, 24 patients received aseptic BTB allografts and 43 patients received BioCleanse-sterilized allografts.

“These results indicate that the sterilization process, BioCleanse, did not demonstrate a statistical difference in clinical outcomes for the BTB allograft at two years,” authors find. “The BioCleanse process may provide surgeons with allografts clinically similar to aseptically-processed allograft tissue with the benefit of addressing donor-to-recipient disease.”

According to Millennium Research Group’s “U.S. Markets for Orthopedic Soft Tissue Solutions 2011” report, more than 457,400 ACL reconstructions are performed annually in the U.S., with 21 percent of those using allograft implants. According to the authors, the use of allograft tissue in ACL reconstruction has been noted to decrease operating time, eliminate donor site morbidity and increase the tissue available for multi-ligament cases. The one disadvantage compared with autografts (the use of one’s own tissue) or metal and synthetic implants, is that disease can be transmitted as a result of an aseptically-processed allograft.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.55 0.59%
FB $102.72 3.20%
GOOG $694.33 2.40%
TSLA $148.16 -0.06%
YHOO $27.61 2.90%


Chart of I:DJI
DOW 16,069.37 +54.99 0.34%
S&P 500 1,871.32 +19.11 1.03%
NASDAQ 4,343.5740 +74.8110 1.75%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs